A structured flowchart illustrating the patient selection process for a long-term COVID-19 follow-up study. The algorithm begins with an initial cohort of patients with a previously confirmed COVID-19 diagnosis who underwent clinical and paraclinical evaluation 2 years post-infection. Inclusion criteria are listed as age over 18 years and agreement to participate, resulting in an initial group of 156 patients. The flowchart then applies specific exclusion criteria, including severe heart failure (NYHA class 3-4), severe lung diseases (COPD GOLD stage 3-5, severe asthma, advanced interstitial lung disease), severe osteoarticular disease, autoimmune diseases, high thrombotic risk pathologies (pulmonary embolism, recent trauma/surgery), acute inflammatory diseases, and neuropsychiatric disorders. The final study group consists of 117 patients. The diagram uses purple rounded rectangles for criteria and blue rectangles for patient counts, connected by logical operators (+) and (-). An illustrative SARS-CoV-2 virion icon is included for thematic context. This flowchart is used to document study methodology in pulmonary rehabilitation and COVID-19 research.

Summary : This figure presents a comprehensive flowchart algorithm for the evaluation and management of chronic spinal pain, detailing the stepwise process from initial assessment through re-evaluation and ongoing management. flowchart: # Nodes : • Evaluation and Management (rectangle) • History (rectangle): Pain history, Medical history, Psychosocial history • Assessment (rectangle): Physical examination, Functional assessment, Psychosocial assessment, Diagnostic testing • Impression (rectangle) • Management plan (rectangle) • Medical and rehabilitation therapies (rectangle) • Diagnostic interventions (rectangle) • Therapeutic interventional management (rectangle) • Re-evaluation (rectangle) • Persistent pain, New pain, Worsening pain (rectangle) • Repeat comprehensive evaluation (rectangle) • Adequate pain relief and improvement in functional status (rectangle) • Continue therapeutic management (rectangle) # Connectors : • Top-down arrows connect each step sequentially. • After "Management plan," three branches lead to "Medical and rehabilitation therapies," "Diagnostic interventions," and "Therapeutic interventional management." • All three branches converge at "Re-evaluation." • "Re-evaluation" splits into two branches: – Left: "Persistent pain, New pain, Worsening pain" → "Repeat comprehensive evaluation" – Right: "Adequate pain relief and improvement in functional status" → "Continue therapeutic management" # Layout : • Vertically oriented flowchart with multiple parallel branches at the management plan stage. • Merging and splitting of branches at re-evaluation, forming a decision point. • All nodes are rectangles with shadow effects for emphasis. # Analysis : • The flowchart provides a systematic, iterative approach to chronic spinal pain management. • Initial steps focus on thorough history and assessment, followed by formulation of an impression and management plan. • Management options are divided into medical/rehabilitation, diagnostic, and interventional therapies. • Re-evaluation is a critical decision point: persistent or worsening pain triggers a repeat evaluation, while adequate relief leads to continued management. • The algorithm emphasizes ongoing assessment and adaptation of treatment based on patient response.

This flowchart delineates a diagnostic and management strategy for cardiovascular (CV) complications in patients undergoing CAR-T cell therapy. The clinical algorithm is organized into three sequential phases: Baseline CV Evaluation, Infusion Monitoring, and Post-Infusion Surveillance. The baseline phase involves CV risk factor assessment, ECG, baseline cardiac biomarkers (e.g., troponin, NT-proBNP), and transthoracic echocardiography (TTE) for patients with pre-existing heart disease. The infusion phase focuses on vital sign assessment, telemetry, monitoring for Cytokine Release Syndrome (CRS), and symptom-driven biomarker assessment. Post-infusion surveillance is risk-stratified based on American Society for Transplantation and Cellular Therapy (ASTCT) CRS grading. High-grade CRS (ASTCT ≥2) triggers tocilizumab administration, repeat cardiac biomarkers, and TTE for Left Ventricular Ejection Fraction (LVEF) assessment. Low-grade CRS requires continued ECG and vital signs monitoring. This infographic serves as a clinical guideline for oncologists and cardiologists to manage cardiotoxicity and systemic inflammatory responses during advanced immunotherapy.